Top

Journal of Gastrointestinal Surgery

Published in:

01-08-2016 | Original Article

Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer

Authors: Yuichiro Kato, Shinichiro Takahashi, Naoto Gotohda, Masaru Konishi

Published in: Journal of Gastrointestinal Surgery | Issue 8/2016

Abstract

Background

The aim of this study was to investigate the prognostic impact of the initial serum postoperative CA19-9 levels in patients with extrahepatic bile duct cancer.

Methods

Data of a total of 143 patients of extrahepatic bile duct cancer with elevated preoperative serum CA19-9 levels (>37 U/ml) who underwent surgery with curative intent were reviewed retrospectively. The patients were divided into the “Normalization group” and “Non-normalization group” (initial postoperative serum CA19-9 ≤37 and >37 U/ml, respectively), and the clinicopathological factors and survival outcomes in these groups were comparatively analyzed.

Results

The cumulative 5-year overall survival (OS) rate and median survival time (MST) were 39.2 % and 42.9 months, respectively, in the Normalization group and 17.9 % and 24.0 months, respectively, in the Non-normalization group (P < 0.001). Presence of jaundice, a poorer histological differentiation grade (G3–4), lymph node metastasis, and initial postoperative serum CA19-9 level (>37 U/ml) were significant independent predictors of a poor prognosis on multivariate analysis.

Conclusion

Non-normalization of the serum CA19-9 level in the initial postoperative phase is a strong predictor of a poor prognosis and is a useful marker to identify patients who would need additional treatments and stricter follow-up.

Akoad M, Jenkins R Proximal biliary malignancy. Surg Clin North Am. 2008; 88: 1409–28, x-xi.CrossRefPubMed

Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001; 234: 507–17; discussion 17–9.CrossRefPubMedPubMedCentral

Veillette G, Castillo CF Distal biliary malignancy. Surg Clin North Am. 2008; 88: 1429–47, xi.CrossRefPubMed

Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg. 2009; 208: 134–47.CrossRefPubMed

Koprowski H, Herlyn M, Steplewski Z, Sears HF Specific antigen in serum of patients with colon carcinoma. Science. 1981; 212: 53–5.CrossRefPubMed

Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979; 5: 957–71.CrossRefPubMed

Magnani JL, Steplewski Z, Koprowski H, Ginsburg V Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19–9 in the sera of patients as a mucin. Cancer Res. 1983; 43: 5489–92.

Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19–9. Clin Chem. 1983; 29: 549–52.

Duffy MJ CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem. 1998; 35 (Pt 3): 364–70.CrossRefPubMed

10.

Hatzaras I, Schmidt C, Muscarella P, Melvin WS, Ellison EC, Bloomston M Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies. HPB (Oxford). 2010; 12: 134–8CrossRefPubMedPubMedCentral

11.

Kau SY, Shyr YM, Su CH, Wu CW, Lui WY Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers. J Am Coll Surg. 1999; 188: 415–20.CrossRefPubMed

12.

Liu SL, Song ZF, Hu QG, Shan D, Hu SB, Li J, et al. Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis. Front Med China. 2010; 4: 457–62.CrossRefPubMed

13.

Kiriyama S, Takada T, Strasberg SM, Solomkin JS, Mayumi T, Pitt HA, et al. TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2013; 20: 24–34.CrossRefPubMed

14.

Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System, Fourth Edition. Lyon: IARC Press; 2010.

15.

International Union Against Cancer (UICC). TNM Classification of Malignant Tumors (2009). 7 ed, Wiley-Liss, New York.

16.

Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006; 24: 2897–902.CrossRefPubMed

17.

Kinsella TJ, Seo Y, Willis J, Stellato TA, Siegel CT, Harpp D, et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol. 2008; 31: 446–53.CrossRefPubMed

18.

Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1997; 4: 551–6.CrossRefPubMed

19.

Motoi F, Rikiyama T, Katayose Y, Egawa S, Unno M Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines. Ann Surg Oncol. 2011; 18: 371–9.CrossRefPubMed

20.

Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Sasaki H, et al. Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. J Surg Oncol. 2014; 110: 422–9.CrossRefPubMed

21.

Japanese Society of Hepato-Biliary-Pancreatic Surgery. General Rules for Clinical and Pathological Studies on Cancer of the Biliary Tract (2013). 6 ed.

22.

Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg. 2007; 31: 1256–63.CrossRefPubMed

23.

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, et al. Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. J Gastrointest Surg. 2013; 17: 1429–39.CrossRefPubMed

24.

Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer. 2005; 103: 1210–6.CrossRefPubMed

Title: Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer
Authors: Yuichiro Kato
Shinichiro Takahashi
Naoto Gotohda
Masaru Konishi
Publication date: 01-08-2016
Publisher: Springer US
Published in: Journal of Gastrointestinal Surgery / Issue 8/2016
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-016-3180-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2016

Laparoscopic Total Gastrectomy with D2 Lymphadenectomy and Side-to-Side Stapled Esophagojejunostomy

Should We Use the Model for End-Stage Liver Disease (MELD) to Predict Mortality After Colorectal Surgery?

C-Reactive Protein and Procalcitonin as Predictors of Postoperative Inflammatory Complications After Pancreatic Surgery

Extra-Adrenal Retroperitoneal Paraganglioma with Extensive Duodenal Invasion and Inferior Vena Cava Tumor Thrombus

Robotic-Assisted Versus Laparoscopic Colectomy Results in Increased Operative Time Without Improved Perioperative Outcomes

Esophageal Apoplexy